Pluristem Therapeutics Inc (PSTI)

[midastouch017]

Pluristem and Innovative Medical Management Co., Ltd. Mutually Agree to Extend the Time to Execute the Definitive Investment Agreements Due to New Chinese Monetary Policy

HAIFA, Israel, Dec. 23, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading developer of placenta-based cell therapy products, today announced that following the recently adopted Chinese policy relating to outbound investments by Chinese companies, it has agreed with China-based Innovative Medical Management Co., Ltd. (stock code: 002173), a publicly listed Chinese Company active in the healthcare industry, to extend the time of execution of the definitive agreements for Innovative Medical’s proposed investment of $30,000,000. Pursuant to the existing term sheet, the parties intended to enter into definitive agreements no later than December 26, 2016. As a result of the recently adopted Chinese policy, the parties now plan to continue the discussions with respect to the definitive agreements until they have received further clarification about such policies, which is expected during the first half of 2017.

This press release does not constitute an offer to sell or a solicitation of an offer to buy Pluristem’s securities and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.